Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
EVO · against 472 other Healthcare companies of similar size
Ranked #305 of 473 · scores higher than 12% of peers
Bars: peers in each 10-point band of the valuation score169 peers with a valuation score of 0–9, including EVO · Click a bar to see the companies
Mainly because of its earnings yield, free cash flow yield and EBITDA yield, which are weaker than most Healthcare peers.
| Metric | EVO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 460 reported | Not reported | 0.5% | — | — | 30% |
| EBITDA yieldHigher is better · 478 reported | -14.8% | 3.6% | 16% | 50% | |
| Free cash flow yieldHigher is better · 200 reported | -35.8% | -5.3% | 6% | 20% | |
| Book yieldHigher is better · 470 reported | 167.5% | 47.5% | 96% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 6.50T IDR (≈$403M) | 99 | 69 | |
| 305 | 530M USD | 8 | 23 | |
| 305 | 487M USD | 8 | 29 | |
| 305 | 455M USD | 8 | 36 | |
| 305 | 486M USD | 8 | 16 | |
| 305 | 551M USD | 8 | 27 | |
| 305 | 508M EUR (≈$559M) | 8 | 21 | |
| 305 | 660M USD | 8 | 43 | |
| 305 | 375M USD | 8 | 46 | |
| 305 | 533M USD | 8 | 36 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score